Physician profile
Pedro A Corzo
NPI 1275699852
$10,517.52
in general payments reported to CMS, 2019-2025
27 companies · $2,394 in 2025
The $2,394 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,253 · 2020: $245 · 2021: $1,409 · 2022: $1,616 · 2023: $1,657 · 2024: $1,943 · 2025: $2,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,994.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,802.34 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,377.46 | 2021-2025 | |
| Amgen INC. | $1,166.76 | 2024-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $659.85 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $629.36 | 2021-2024 | |
| Gilead Sciences, INC. | $525.00 | 2019-2025 | Livdelzi |
| Merck Sharp & Dohme LLC | $455.19 | 2019-2023 | Verquvo |
| Lilly USA, LLC | $330.09 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.74 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $281.53 | 2019-2023 | |
| Ibsa Pharma INC. | $250.00 | 2023-2024 | Tirosint, Licart |
| Janssen Pharmaceuticals, INC | $198.21 | 2019-2022 | |
| Exact Sciences Corporation | $186.51 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $176.35 | 2023-2024 | Arexvy, Shingrix |
| Intra-Sana Laboratories | $159.62 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $137.21 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Allergan, INC. | $124.99 | 2019 | |
| Xeris Pharmaceuticals, INC. | $124.58 | 2025 | Recorlev |
| Sanofi-Aventis U.S. LLC | $110.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.12 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $85.47 | 2025 | |
| Ardelyx, INC. | $70.09 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $55.68 | 2024 | Voquezna |
| Pfizer INC. | $37.63 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $17.60 | 2025 | Zoryve |
| Horizon Therapeutics Plc | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Corzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.